Latest news with #patents
Yahoo
a day ago
- Business
- Yahoo
Annovis Completes Full Patent Transfer to Crystal Buntanetap
Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families. All patents are filed internationally, securing global coverage of buntanetap. MALVERN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the 'Company'), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that all Company's patents have been successfully transferred from the original form of buntanetap and rewritten to cover the new crystal form. Every patent family is now represented for both forms of the Company's drug candidate, securing comprehensive protection, which extends to 2046. Building on its foundational patent for the treatment of chronic neurodegenerative conditions, the Company has systematically expanded its coverage to include patents for the use of the original compound. Since then, Annovis has developed a robust IP portfolio which includes patents protecting the composition of matter, mechanism of action, applications of buntanetap for multiple indications, and its combination with other drugs. Recently, the Company identified and characterized a new crystalline form of buntanetap with improved solid-state stability and comparable pharmacokinetic (PK) properties. A series of animal and human studies demonstrated the bioequivalence of both forms of buntanetap as they exhibit identical systemic exposure. These findings were presented at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto, and the poster is now available in the Media Library on the Company's website. Annovis previously secured protection for the composition of matter and manufacturing process of the crystalline form. However, as of this month, the Company has successfully completed the transfer of all IP inventions, extensions, and combinations from the original buntanetap to the new form, ensuring comprehensive coverage of its drug candidate on two fronts: one preserving the legacy of the semi-crystalline buntanetap (pink) and the other dedicated to the crystalline form (blue).'This is a major milestone for our company,' said Maria Maccecchini, Ph.D., President and CEO of Annovis. 'With full IP protection now in place for both forms of buntanetap, we are well-positioned to continue its development and fully explore its therapeutic potential. Buntanetap's unique mechanism of action allows it to suppress multiple pathologies simultaneously, and it may offer even better advantages when complemented by other drugs such as GLP-1 agonists, PDE5 inhibitors, and statins. This opens doors to possible pipeline expansions and broader clinical applications as part of our strategic growth.' This IP milestone for crystal buntanetap complements another significant step – last year the FDA approved the use of the new form for the pivotal Phase 3 clinical trial in early AD (NCT06709014), based on its safety and PK data. The trial was initiated earlier this year with participants (MMSE 21-28, pTau217+) receiving either placebo or crystal buntanetap daily for 18 months. The study is actively underway with over 75 sites secured across the US and more patients entering each week, bringing us closer to reaching our enrollment goal by day. To find more information about the study, visit our updated Patient Portal or the official page. About Annovis Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit and follow us on LinkedIn, YouTube, and X. Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at Forward-Looking StatementsThis press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company's SEC filings under 'Risk Factors' in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA Investor Contact:Alexander Morin, Strategic CommunicationsAnnovis Bioir@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Atomera Inc (ATOM) Q2 2025 Earnings Call Highlights: Strong Demand and Strategic Partnerships ...
Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Atomera Inc (NASDAQ:ATOM) is experiencing increased wafer activity, indicating strong demand for their product initiatives. The company has reached a new high in customer wafer runs, suggesting growing interest and potential production decisions. Atomera Inc (NASDAQ:ATOM) is actively engaged with transformative customers, conducting large-scale demo runs that could lead to significant production decisions. The company is expanding its focus on gallium nitride for RF applications, collaborating with InSIS to enhance technology characterization. Atomera Inc (NASDAQ:ATOM) has surpassed 400 issued and pending patents, showcasing its innovation and strong intellectual property portfolio. Negative Points The delay in ST Micro's rollout of BCD 110 with MST to 300 millimeter wafers is a setback, affecting the timeline for process qualification. Atomera Inc (NASDAQ:ATOM) reported a GAAP net loss of $5 million for Q2 2025, an increase from the previous year's loss. Operating expenses have risen due to increased R&D and payroll costs, impacting the company's financials. The company is facing challenges in hiring additional team members to support the high level of customer activity. There is uncertainty regarding the timing of milestone payments from ST Micro, which could affect revenue expectations. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with ATOM. Q: Can you elaborate on the impact of ST Micro's decision to move directly to 300mm wafers and how it affects Atomera's timeline and processes? A: Scott Bebo, President and CEO, explained that while the shift to 300mm wafers by ST Micro will delay the rollout of BCD 110 with MST, the work done on 200mm wafers is still valuable. ST Micro has gained significant expertise in depositing MST, which will aid in the transition to 300mm. Although there are some logistical challenges, such as acquiring a 300mm tool, the integration work is expected to proceed more smoothly due to the experience gained so far. Q: What is the likelihood of milestone payments from ST Micro next year, given the current progress? A: Scott Bebo expressed confidence in achieving milestone payments next year. He noted that Atomera has demonstrated compelling performance levels to ST Micro, which should encourage them to move quickly towards production. However, he refrained from making definitive statements about the exact timing of process qualification. Q: How has Atomera's partnership with an unnamed equipment vendor progressed, and what are the focus areas? A: The partnership, primarily focused on gate-all-around devices, has expanded into other areas as well. Scott Bebo mentioned that they have been working closely with the vendor to develop test data and engage with customers. Weekly meetings and strategic discussions are ongoing to address customer needs and enhance collaboration. Q: What are Atomera's plans to capitalize on the growing demand for data centers, particularly concerning MST SPX? A: Scott Bebo highlighted that Atomera's work in power technologies, including MST SPX and gallium nitride, is well-suited for data centers. These technologies aim to reduce power consumption and improve efficiency. Additionally, Atomera is exploring opportunities in 48-volt power devices, which are becoming standard in AI data centers. Q: Does Atomera's membership in the National Semiconductor Technology Center (NSTC) increase the chances of receiving CHIPS Act subsidies? A: Frank Lorencio, CFO, indicated that while direct funding from the CHIPS Act is not the primary goal, membership in NSTC enhances access to testing and prototyping facilities. This access is crucial for developing and testing advanced transistor structures, which indirectly increases the likelihood of receiving subsidies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Irish Times
4 days ago
- Business
- Irish Times
TD calls for referendum on joining EU patent court to be held before next summer
The delayed referendum on Ireland joining the European Union's Unified Patent Court (UPC) should be held before next summer, according to Fianna Fáil TD Malcolm Byrne . He said Ireland's membership of Europe's unified patent system would 'make life easier' for Irish inventors, content creators and small businesses. The Irish Times reported on Monday that there have been tentative moves within Government to revive the referendum. The vote on Ireland joining the 18 other EU member states that have signed up to the UPC system was originally due to take place in June 2024. READ MORE Mr Byrne, a Wicklow-Wexford TD, was to be Fianna Fáil's director of elections for the referendum. However, the last government decided to defer the UPC vote in the aftermath of the defeat of the Family and Care referendums to allow more time for public engagement on the matter. In recent months the Department of Enterprise has contacted business organisations and Government departments, seeking feedback on the level of engagement taking place on the UPC issue and views on the appropriate timing of a rescheduled vote. The UPC is designed to provide a one-stop shop court for litigation on patents. The court's decisions will be binding on participating EU member states. Business groups have long called for Ireland to join the UPC. The Department of Enterprise said the Government is committed to holding the referendum, but 'the timing remains under consideration'. Mr Byrne urged the Government to commit to a referendum and an 'informed campaign' before next summer. He said: 'For someone who invents something in Ireland to protect that idea or product, they have to seek a patent in every jurisdiction in the European Union and the recognition of the creation is not always enforceable in a uniform way. 'Ireland joining the unified patent system will make that much easier and it will heavily reduce costs and the administrative burden on inventors.' [ Ireland fined €1.54m for delay in writing EU work-life balance directive into law Opens in new window ] Mr Byrne added: 'This is probably not the issue that most people are thinking about but for inventors and businesses it is really important.' Ireland has to vote on it because the Constitution requires a vote for joining such a European structure, he said. 'The decision will mean transferring some judicial sovereignty, but only in the area of patents, to the new court. It has only to do with patents.' In May, Mr Byrne asked Taoiseach Micheál Martin in the Dáil if he would consider holding the UPC referendum on the same day as the presidential election this year. Mr Martin said he did not anticipate that happening, but he indicated his support for Ireland joining the UPC. He added: 'We need to prepare properly for when we decide to have a referendum. We have to do the homework and be in a position to convince people of the merits of the case.' [ Ireland is exposed as Maga right attempts to take on Big Tech regulation Opens in new window ]
Forbes
01-08-2025
- Business
- Forbes
U.S. Government Seeks 1-5% Cut Of Patent Royalties Annually
There are not many holy grails in Silicon Valley, but patents are one of them, since they are the lifeblood of technology and any intellectual property that is at the heart of innovation. Since the Wall Street Journal wrote the story of the U.S government seeking patent royalties, my phone has been ringing nonstop with calls from venture capitalists, tech entrepreneurs and some major tech companies who are are deeply opposed to this action. The Commerce Department's recent proposal wants to overhaul the U.S. patent fee structure. This proposal signals a potentially seismic shift for American innovation—a topic close to the heart of the technology sector. For over two centuries, the U.S. patent system has operated on a flat-fee model, typically costing inventors and corporations several thousand dollars—capped at around $10,000 spread over the years—to obtain and maintain a patent. This predictability has been a cornerstone, allowing both garage inventors and tech giants to plan their IP strategies with a high degree of certainty. The current proposal under consideration, however, would require patent holders to pay 1- 5% of their patent's assessed value annually, functioning much like a property tax on intellectual property. The intent is clear: generate billions of dollars in recurring revenue for the federal government, partly to address budget deficits and fund policy goals, all without direct tax hikes. But the implications of this proposal are far-reaching, especially for the technology sector. Instead of a fixed, predictable cost, the new model exposes innovators to higher and potentially variable annual fees, directly tied to how their IP is valued on the open market. For tech heavyweights—think Apple, Intel, IBM, Amazon, or biotech leaders with sprawling patent portfolios—the new cost could run into the tens or even hundreds of millions annually. For startups and small inventors, already stretched thin, the prospect of higher, value-based fees could become a new hurdle to entry, dissuading filings and R&D investment. Venture capital firms, which often see patents as necessary collateral, may look elsewhere, favoring regions with more predictable costs and friendlier policies. The practicalities present another challenge: How would the government assess and tax the 'value' of a patent? Such valuations are inherently subjective, fraught with legal and financial ambiguity. A clear, reliable framework does not currently exist—and implementing one risks bureaucratic backlogs and costly disputes. Unsurprisingly, the response from the business and innovation community has been swift and critical. Major trade organizations, tech firms, and IP attorneys have sounded alarms over what they see as double taxation, since companies already pay taxes on the revenues generated from IP. The tech sector warns this could shift the U.S. further from global norms and jeopardize its position as a leading innovation hub, as no other country currently levies a value-based patent tax. The Commerce Department's proposal is not just an administrative adjustment; it represents a fundamental reimagining of how America incentivizes, protects, and taxes innovation. While the potential fiscal windfall for the government is sizable, the policy risks discouraging inventors and entrepreneurs, dampening the very spirit of invention it aims to foster. The coming debate, and its outcome, will reveal America's priorities at the intersection of revenue generation and innovation in leadership. If the U.S. government is serious about moving forward with this proposal, expect fierce opposition from Silicon Valley and other major companies that rely on patents to protect their intellectual property. They will vigorously fight the proposal and do everything in their power to defeat it. Disclosure: Apple, Intel and Amazon subscribe to Creative Strategies research reports along with many other high tech companies around the world.
Forbes
31-07-2025
- Business
- Forbes
The AI Patent Revolution: Why Young Professionals Should Think Like Inventors
Arvin Patel is the Chief Licensing Officer at Nokia and a member of the Board of Directors for the UCLA Technology Development Group. While headlines warn of artificial intelligence replacing millions of jobs, they overlook a fundamental shift occurring right under our noses: The surge in AI innovation is generating unprecedented demand at the United States Patent and Trademark Office (USPTO). Major corporations are also actively seeking employees who understand both AI capabilities and intellectual property strategy. These aren't jobs that AI will replace—they're jobs that exist because of AI. Being an inventor on over 50 patents during my career at companies such as IBM, NorthPole and TiVo, I have observed that the most profitable innovations often stem from the simplest observations. What sets today apart? AI is transforming everyday solutions into scalable, patentable systems that can generate income for decades. Areas Of Opportunity The data reveals what mainstream media often overlooks: AI patent applications are skyrocketing, particularly for generative AI, with many filings originating from individual inventors and small teams rather than tech giants. While automation eliminates repetitive tasks, it simultaneously creates new opportunities for those who can identify problems and translate solutions into protected intellectual property. Just as typing became essential in the 1980s and internet proficiency became necessary in the 2000s, understanding artificial intelligence—and its intellectual property implications—is now a fundamental skill for economic participation. In other words, technology isn't replacing human creativity—it's amplifying it. As someone who has navigated multiple technological transitions throughout my career, I understand how overwhelming this wave of economic and technological change can feel. But young professionals, take heart—this transformation is also unlocking new opportunities at every level of education and experience. How Young Professionals Can Use AI To Their Advantage Young minds have always been good at identifying problems and inefficiencies with the traditional way of doing things. Especially creative individuals can come up with novel, clever ideas to solve these problems. Historically, the final step of building a working solution to the problem has often been prohibitively expensive and time-consuming—until now. AI has made it possible for young inventors to build solutions to problems in a way that was not possible even five years ago. For example, many companies struggle with inefficient meeting practices that drain productivity. Remote and hybrid work has made it even harder to maintain focus during virtual meetings. Today, a thoughtful entrepreneur could use AI to develop a platform that analyzes meeting dynamics in real time, automatically generates action items and provides productivity insights while filtering out irrelevant discussions. And if you understand patents, you now possess a process that hundreds of companies might license. AI can enable entrepreneurs to bridge the gap between having a good idea and generating wealth through innovation. Moreover, the patent system is more accessible than many realize. Provisional patent applications can cost as little as $65 for individual inventors who qualify for micro-entity status, which is less than a typical business dinner. The USPTO offers free educational resources for first-time inventors, and local inventor groups often provide mentorship. Online courses also teach IP fundamentals in a matter of weeks, not years—making it feasible to learn while maintaining a full-time career. Entrepreneurs across the country should look beyond Silicon Valley for inspiration. The FDA maintains a public list of approved AI-enabled medical devices. In 2023, 171 new devices were added that year alone. This marks a dramatic increase from an average of just seven approvals annually between 1995 and 2015. While many of these devices originate from established medical companies, this surge also highlights innovations from a variety of sources, including healthcare practitioners who have identified clinical gaps and developed systematic solutions. Many successful AI patents originate from individuals who recognize inefficiencies in their daily tasks and create systematic solutions. The crucial aspect is to document not only what AI accomplishes but also how it resolves specific issues in ways that weren't obvious before. In an economy where AI performs routine tasks, humans must own the innovations that shape AI's capabilities. The question isn't whether you will work alongside AI—it's whether you will own the ideas that determine the evolution of that partnership. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
